ClinicalTrials.gg

Program

SHR-9839

A development code. Also written as “SHR-9839(sc) for Injection”, “SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion” and “SHR-9839(sc)”.

Its studies are mostly in Esophageal Squamous Cell Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jun 2, 20246 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine66 open or runningphase 2since Jun 2, 2024Apr 19, 2023Dec 2026phase 2 · NCT06915142
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-9839 (sc), phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05836948 · 174 planned · China
  2. Jun 2, 2024Phase 2 study in Advanced Solid TumorsNCT06474455 · 156 planned · China
  3. Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
  4. Jul 1, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221 · 210 planned · China
  5. Nov 13, 2025Phase 2 study in Solid TumorNCT07229638 · 70 planned · China
  6. Aug 3, 2026Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT07751341 · 84 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221
  3. Apr 2027Primary completion: phase 2 study in Solid TumorNCT07229638
  4. Dec 2027Primary completion: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT07751341

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07751341Advanced Esophageal Squamous Cell Carcinoma · China2RecruitingDec 202784
NCT07229638Solid Tumor · China2RecruitingApr 202770
NCT07059221Squamous Cell Carcinoma of Head and Neck · China2RecruitingMar 2027210
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT06474455Advanced Solid Tumors · China2RecruitingJun 2029156
NCT05836948Advanced Solid Tumor · China1RecruitingMay 1, 2026174

How it is read

Names in the registry

  • “SHR-9839(sc) for Injection”, 1 entry
  • “SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion”, 1 entry
  • “SHR-9839(sc)”, 1 entry
  • “SHR-9839 for Injection”, 1 entry
  • “SHR-9839 for Injection (sc)”, 1 entry

Codes read as this program: SHR9839.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.